Anthropic 科学家与 6 家开发新药的组织建立深度研究合作，并启动自有药物发现项目，相关成果仍多处于临床前阶段。据 Rohan Paul 转述，Claude 约一个月生成约 3.5 万个抗体设计，为一家单人生物技术公司协调 11 个外部实验室，并发现人类审查者漏掉的 7 个生产问题。Anthropic 自有项目中的肌营养不良症工作最早可能在 2028 年底进入人体试验。
同一件事，精选收录的是《Anthropic 公布 Claude 参与新药研发进展，最快 2028 年底进入人体临床试验》
Anthropic now uses Claude inside real drug programs at 6 companies and runs its own, including muscular dystrophy work that could reach human trials as soon as late 2028.
Claude handled far more than molecule ideas: it generated roughly 35K antibody designs in about a month, coordinated 11 outside labs for a one-person biotech, and caught 7 manufacturing issues human reviewers missed.
The work remains mostly preclinical, though Anthropic’s in-house programs could put a drug into human trials as soon as late 2028.
Over the past few months, Anthropic scientists have engaged in deep research partnerships with six organizations developing new medicines. We've also begun drug discovery efforts of our own. In doing so, we’ve learned much more about how Claude can support the many stages of drug development. In this blog post, we share some early results from these efforts, and describe how this work fits in with our wider ambitions in the life sciences. https://www.anthropic.com/research/early-progress-drug-development在 X 查看被引用的帖子
来源：Rohan Paul · x.com